Ozempic Vision Loss Lawsuit — August 2026 Status: More than 200 lawsuits alleging that Ozempic and other GLP-1 drugs caused sudden, permanent vision loss (NAION) are now consolidated in federal court (MDL 3163, Eastern District of Pennsylvania, Judge Karen S. Marston). The case count more than doubled between May and August 2026. Alabama patients generally have two years from injury to file. Consultations are free: (205) 407-6009.
Ozempic, Wegovy, Mounjaro, Zepbound, and other GLP-1 medications have transformed diabetes care and weight loss, but for a small group of patients, these drugs are now linked to a devastating side effect: non-arteritic anterior ischemic optic neuropathy (NAION), a sudden loss of vision that is usually painless, often discovered on waking, and typically permanent. If you took a GLP-1 medication and suffered sudden vision loss in one or both eyes, Fob James Law Firm is reviewing Alabama cases now.
What Is NAION and How Is It Linked to Ozempic?
NAION is often described as a “stroke of the optic nerve.” Blood flow to the front of the optic nerve is interrupted, nerve tissue dies, and the vision it served does not come back. There is no established treatment that reverses NAION once it happens.
In 2024, researchers at Harvard’s Massachusetts Eye and Ear reported that patients taking semaglutide (the active drug in Ozempic and Wegovy) developed NAION at several times the expected rate — a reported 4.3x higher risk in diabetic patients and roughly 7.6x higher in patients taking it for weight loss. As of August 2026, the FDA has not required a NAION warning on U.S. labels — a central allegation in the litigation.
Symptoms of Ozempic-Related Vision Loss
NAION usually arrives without pain, and often overnight. Many people first notice it on waking. The signs worth acting on immediately are sudden blurred or dimmed vision in one eye, a dark or missing area in the field of view that most often takes the lower half, colors that look washed out, or a shadow like a curtain drawn across part of your sight. The absence of pain is exactly why people wait, and waiting costs vision. No treatment reliably reverses NAION, the loss is frequently permanent, and the second eye can be at risk, so sudden vision changes call for an ophthalmologist the same day. Getting that care protects your health first. It also creates the medical record any later claim depends on.
What the Research Shows About Semaglutide and NAION
The study that changed this litigation came from researchers at Harvard’s Massachusetts Eye and Ear, published in JAMA Ophthalmology in 2024. It reported that patients prescribed semaglutide for type 2 diabetes developed NAION at more than four times the rate of matched patients taking other medications, and that patients prescribed it for weight management developed it at more than seven times the rate. A Netherlands analysis covering over 400,000 patients reported roughly double the risk among diabetic semaglutide users. In 2026, a Department of Veterans Affairs analysis published in JAMA Network Open and covering more than 588,000 patients reported a 35 percent higher NAION rate among GLP-1 users than among comparable patients taking SGLT2 inhibitors.
Researchers still debate the biological mechanism, and no epidemiological study proves what caused any one person’s vision loss. That is a question for the medical experts in an individual case. What this body of research did do is persuade regulators outside the United States to act, and it forms the scientific foundation plaintiffs are building these claims on.
The GLP-1 Vision Loss Litigation (MDL 3163)
In December 2025, the Judicial Panel on Multidistrict Litigation consolidated GLP-1/NAION lawsuits into MDL 3163 before Judge Karen S. Marston in the Eastern District of Pennsylvania. The defendants are Novo Nordisk (Ozempic, Wegovy, Rybelsus) and Eli Lilly (Mounjaro, Zepbound). Plaintiffs allege the manufacturers knew or should have known of the NAION signal and failed to warn patients and doctors.
Where things stand (August 2026): roughly 200 cases were pending in the MDL as of early August, up from 86 in May, and the court held a “Science Day” in June 2026 where both sides presented the medical evidence on the semaglutide–NAION link. The litigation is early: no bellwether trials have been scheduled and no settlements have been announced.
Ozempic Stomach Paralysis and Gastroparesis Claims
Vision loss is not the only injury in this litigation, and it is not the largest group of cases. A separate federal proceeding, MDL 3094, consolidates claims that GLP-1 drugs caused gastroparesis, often called stomach paralysis, along with intestinal obstruction and severe gastrointestinal injury. That docket held roughly 3,928 pending cases as of August 2026, far more than the vision-loss docket, and it sits before the same judge in the same district. Plaintiffs allege the drugs slow gastric emptying well beyond what the labels disclosed, leaving some patients with chronic vomiting, malnutrition, and repeated hospitalizations that continue after they stop taking the drug. If you took Ozempic, Wegovy, Mounjaro, or Zepbound and developed severe stomach problems rather than vision loss, you may still have a claim, and our attorneys evaluate both tracks in the same free review.
What Regulators Outside the U.S. Have Already Done
The core allegation in the GLP-1 vision loss litigation is not that the risk was unknowable. It is that regulators in other countries acted on it while U.S. labels stayed silent.
July 2024 — the signal. Researchers publishing in JAMA Ophthalmology reported the elevated NAION rates described above, and drug regulators in several countries opened reviews.
June 2025 — Europe. The European Medicines Agency concluded that NAION is a “very rare” side effect of semaglutide and required label changes across Europe. The World Health Organization issued its own statement on semaglutide and NAION the same month.
February 2026 — United Kingdom. The MHRA told prescribers that semaglutide “may be very rarely associated with NAION,” which it defined as affecting up to 1 in 10,000 patients, and cited European evidence of an approximately two-fold increase in relative risk. Its instruction was direct: discontinue semaglutide if NAION is confirmed.
July 2026 — Australia. The Therapeutic Goods Administration issued a class-wide warning covering semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro), liraglutide (Saxenda) and dulaglutide (Trulicity). It described NAION as “a rare but serious condition that may result in permanent visual impairment, including blindness,” estimated two to 18 additional cases per 100,000 GLP-1 users per year, and told patients to seek urgent ophthalmological examination for sudden vision loss, including partial loss of vision.
August 2026 — the United States. U.S. labels still carry no NAION warning.
That gap is what the lawsuits are about. Plaintiffs allege the manufacturers had the same safety data on both sides of the Atlantic, warned patients in Europe, the U.K. and Australia, and left American patients and their doctors without the same information.
Which GLP-1 Drugs and Manufacturers Are Involved
The litigation covers a family of drugs, not one product, and people often do not realize the medication they took belongs to it. Novo Nordisk makes semaglutide, sold as Ozempic for type 2 diabetes, Wegovy for weight management, and Rybelsus in tablet form. Eli Lilly makes tirzepatide, sold as Mounjaro for diabetes and Zepbound for weight loss. Both companies are defendants in the vision-loss MDL. Older drugs in the same class, including liraglutide sold as Victoza and Saxenda, have also drawn scrutiny in the published research.
Two points matter for anyone deciding whether to call. First, the brand you were prescribed does not decide whether you have a claim; the drug class and your injury do. Second, compounded semaglutide from a medical spa or online seller counts too. Those products carry their own set of problems, and patients who used them are frequently the ones who assume no one will take their case. Bring us what you took and we will sort out which defendant it points to.
Who May Qualify for an Ozempic Vision Loss Claim in Alabama
- You were prescribed Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Saxenda, or Victoza (prescription use, not compounded or gray-market versions); and
- You were diagnosed with NAION or suffered sudden, painless vision loss, often described as blurry or dim vision on waking, a dark or shadowed area in one eye’s field, or sudden partial or full vision loss; and
- The vision loss came after you started the medication.
Bring whatever records you have: prescription history, ophthalmology records, and the date your vision changed. We will handle the rest of the workup.
Evidence That Builds an Ozempic Vision Loss Claim
These cases are won on documentation, and most of it already exists in your medical file. The core records are your prescription and pharmacy history, showing which GLP-1 drug you took, at what dose, and over what period; your ophthalmology records, including the NAION diagnosis itself; and the imaging behind that diagnosis, which typically means optical coherence tomography scans, visual field testing, and fundus photography of the optic nerve.
The timeline carries the most weight, because the defense will argue your vision loss came from something else. Diabetes, high blood pressure, sleep apnea, and a small optic disc are all genuine NAION risk factors, and having them does not disqualify you. It means the medical proof has to be built carefully, which is the work. Also valuable: a note of when symptoms began, records of any emergency visit, and documentation of how the loss changed your work and daily life. If you no longer have pharmacy records, we can obtain them for you.
The Alabama Filing Deadline
Alabama’s statute of limitations for personal injury claims is generally two years (Ala. Code § 6-2-38). For a vision-loss claim, the clock usually starts at the injury. Waiting costs evidence even when it doesn’t cost the claim. If your vision loss was recent, the best time to call is now.
How Alabama Product Liability Law Applies
Claims filed by Alabama residents proceed under the Alabama Extended Manufacturer’s Liability Doctrine, the state’s framework for holding a manufacturer responsible when a product was unreasonably dangerous as it left their hands. In the GLP-1 cases the theory is failure to warn. The allegation is not that these drugs should never have been sold, and many patients benefit from them. It is that Novo Nordisk and Eli Lilly learned of an optic nerve risk and did not put adequate warnings in front of patients and prescribing physicians in time for them to weigh it.
Alabama’s two-year deadline under Ala. Code § 6-2-38 governs, and when that clock started can itself be contested for an injury whose cause was not obvious at the time. Alabama’s contributory negligence rule, which can bar recovery from a plaintiff even 1 percent at fault, carries far less weight in a pharmaceutical warning case than in a traffic case, though it is one more reason to have counsel who tries cases in this state rather than a national intake service.
What Ozempic Cases May Be Worth
No settlement exists in either GLP-1 MDL, and no bellwether trial has produced a verdict. Any site quoting you a specific Ozempic settlement figure is estimating, not reporting, and you should read those numbers with that in mind.
What can be said honestly is what drives value in a pharmaceutical injury case: how severe and how permanent the injury is, and irreversible vision loss in one or both eyes sits at the serious end of that scale; medical costs already incurred and reasonably expected; lost income and reduced earning capacity, which can be substantial when sight loss ends a career; the strength of the timeline connecting your prescription to your symptoms; and whether the evidence developed in discovery supports punitive damages based on what the manufacturers knew and when. Every case resolves on its own facts. We will tell you what yours looks like once we have read the records, not before.
Ozempic Litigation Updates
August 2026 — Filings Pass 4,100. Federal GLP-1 filings across the two MDLs climbed past 4,100 cases, with roughly 200 in the NAION vision-loss docket and about 3,928 in the gastroparesis proceeding. New vision-loss cases continue to be filed and transferred in.
July 2026 — Australia adds NAION warnings. Australian regulators were reported to have added NAION warnings to GLP-1 labeling, another step taken abroad while the FDA has still not required a NAION warning in the United States.
June 2, 2026 — Science Day. Judge Marston heard scientific presentations from both sides on the link between semaglutide-class drugs and NAION. Science Day is the customary step before a court sets its discovery and bellwether path.
December 2025 — MDL 3163 created. The Judicial Panel on Multidistrict Litigation consolidated federal NAION vision-loss cases in the Eastern District of Pennsylvania before Judge Karen S. Marston, who also presides over the gastroparesis MDL.
Steps to Take If You Lost Vision After Taking Ozempic
See an ophthalmologist right away if the change is recent, because the other eye can be at risk and the examination findings matter. Do not stop a prescribed medication on your own; talk to the doctor who prescribed it. Keep your pharmacy records, your pens or packaging if you still have them, and any message you sent a provider about side effects. Write down when the symptoms started while your memory of it is clear. Then talk to a lawyer well before the two-year window closes, because building the medical timeline takes longer than most people expect.
Why Alabama Families Call Fob James Law Firm
Mass tort advertising is loud, and most of it comes from out-of-state call centers that sign clients and forward the file elsewhere. Fob James Law Firm is a Birmingham trial firm. You speak with an attorney, not an intake screener reading a script, and the lawyer you meet stays on your case. The firm brings over 40 years of combined experience and more than $100 million recovered for injured people across Alabama.
Vision-loss cases in particular reward careful medical work, because the defense in every one of them will point at your diabetes, your blood pressure, or your optic disc anatomy and argue the drug had nothing to do with it. Answering that takes a firm willing to build the record properly with treating physicians and retained experts. There is never a fee unless we recover for you, and the consultation costs nothing.
We are a Birmingham-based injury firm that handles mass tort claims for Alabama families, and our attorneys work alongside the national litigation teams prosecuting the GLP-1 cases. You get local counsel who answers the phone and a seat at the national table. There is no fee unless we recover for you.
Ozempic Vision Loss Lawsuit FAQs
Is there a class action for Ozempic vision loss?
Not a class action. The cases are consolidated in a multidistrict litigation (MDL 3163) in Pennsylvania federal court. Each plaintiff keeps an individual claim valued on their own injuries, which for permanent vision loss can be substantial.
How much does it cost to file an Ozempic lawsuit?
Nothing up front. We handle GLP-1 vision loss cases on a contingency fee. The consultation is free and we only get paid if we recover money for you.
What if I took Wegovy, Mounjaro, or Zepbound instead of Ozempic?
The litigation covers the GLP-1 class, including Novo Nordisk’s Ozempic, Wegovy, and Rybelsus and Eli Lilly’s Mounjaro and Zepbound. If you took any GLP-1 medication and suffered sudden vision loss, you may qualify.
How long do I have to file in Alabama?
Generally two years from the injury under Alabama’s statute of limitations, and the practical window for building a strong case is shorter. A free attorney case review will pin down your specific deadline.
What is NAION in plain language?
NAION stands for non-arteritic anterior ischemic optic neuropathy. Blood flow to the optic nerve is interrupted, the nerve is damaged, and vision is lost in that eye, usually suddenly and usually without pain. It is sometimes described as a stroke of the optic nerve, and the damage is generally permanent.
Has the FDA required a NAION warning on Ozempic?
Not as of August 2026. The U.S. label warns about vision changes generally, but no NAION-specific warning has been required here, while the European Medicines Agency, the World Health Organization, and Australian regulators have all addressed NAION risk. That gap between what regulators abroad did and what U.S. patients were told is central to the failure-to-warn claims.
Can I still file if I have diabetes or other NAION risk factors?
Yes. Most people prescribed these drugs have diabetes or obesity, and both carry their own vascular risks. Those conditions make the medical causation work more detailed; they do not automatically defeat a claim. Have the records reviewed before you rule yourself out.
How long will the Ozempic litigation take?
Longer than anyone would like. MDL 3163 was created in December 2025, Science Day was held in June 2026, and discovery and bellwether selection follow from there. Cases of this type commonly run years before any resolution, which is why the Alabama filing deadline matters now rather than later.
Do I have to travel to Pennsylvania for my case?
No. Cases are filed and coordinated through the MDL, but you work with our attorneys here in Alabama. Most clients never appear in a Pennsylvania courtroom.
Talk to an Alabama Ozempic Lawyer Today
Sudden vision loss changes everything — work, driving, independence. If it happened after a GLP-1 prescription, you deserve answers and, if the evidence supports it, compensation. Call Fob James Law Firm, LLC at (205) 407-6009 or contact us online. 2226 1st Ave S, Suite 105, Birmingham, AL 35233. Free consultation, no fee unless we win.